1. Chemotherapy-induced gut toxicity: are alterations to intestinal tight junctions pivotal?

   • Hannah R. Wardill
   • Joanne M. Bowen
   • Rachel J. Gibson

   Review Article 30 September 2012 Pages: 627 - 635

   

2. PPAR signaling pathway may be an important predictor of breast cancer response to neoadjuvant chemotherapy

   • Y. Z. Chen
   • J. Y. Xue
   • J. Wu

   Original Article 19 August 2012 Pages: 637 - 644

   

3. Phase II study of irinotecan and cisplatin with concurrent split-course radiotherapy in limited-disease small cell lung cancer

   • Minoru Fukuda
   • Yoichi Nakamura
   • Shigeru Kohno

   Original Article 22 August 2012 Pages: 645 - 651

   

4. Disposition and metabolism of ¹⁴C-dovitinib (TKI258), an inhibitor of FGFR and VEGFR, after oral administration in patients with advanced solid tumors

   • Anne-Charlotte Dubbelman
   • Alana Upthagrove
   • Jan H. M. Schellens

   Original Article 22 August 2012 Pages: 653 - 663

   

5. A phase II study of docetaxel and oxaliplatin combination in recurrent gastric cancer patients after fluoropyrimidine and/or cisplatin adjuvant treatment: a Korean Cancer Study Group Protocol ST06-02

   • Yoon Hee Choi
   • Sang Cheul Oh
   • Hye Jin Kang

   Original Article 25 August 2012 Pages: 665 - 672

   

6. A phase I and pharmacokinetic study of elisidepsin (PM02734) in patients with advanced solid tumors

   • R. Salazar
   • R. J. Jones
   • T. R. J. Evans

   Original Article 25 August 2012 Pages: 673 - 681

   

7. A phase II study of concurrent chemoradiotherapy with weekly docetaxel and cisplatin in advanced oesophageal cancer

   • Hyun-Jeong Shim
   • Dae-Eun Kim
   • Ik-Joo Chung

   Original Article 30 August 2012 Pages: 683 - 690

   

8. Phase I/II study of S-1 combined with biweekly irinotecan chemotherapy in previously treated advanced non-small cell lung cancer

   • Hiroki Goya
   • Hiroshi Kuraishi
   • Tomonobu Koizumi

   Original Article 01 September 2012 Pages: 691 - 697

   

9. Phase I and pharmacokinetic study of IHL-305 (PEGylated liposomal irinotecan) in patients with advanced solid tumors

   • Jeffrey R. Infante
   • Vicki L. Keedy
   • Howard A. Burris III

   Original Article 02 September 2012 Pages: 699 - 705

   

10. Everolimus synergizes with gefitinib in non-small-cell lung cancer cell lines resistant to epidermal growth factor receptor tyrosine kinase inhibitors

    • Song Dong
    • Xu-Chao Zhang
    • Yi-Long Wu

    Original Article 02 September 2012 Pages: 707 - 716

    

11. Single-dose pharmacokinetics of lenalidomide in healthy volunteers: dose proportionality, food effect, and racial sensitivity

    • N. Chen
    • C. Kasserra
    • H. Lau

    Original Article 06 September 2012 Pages: 717 - 725

    

12. Population pharmacokinetics of farletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer

    • Colm Farrell
    • Charles Schweizer
    • Martin D. Phillips

    Original Article Open access 07 September 2012 Pages: 727 - 734

    

13. Phosphorylated AMP-activated protein kinase expression associated with prognosis for patients with gastric cancer treated with cisplatin-based adjuvant chemotherapy

    • Byung Woog Kang
    • Ji Yun Jeong
    • Jong Gwang Kim

    Original Article 07 September 2012 Pages: 735 - 741

    

14. A biomarker profile for predicting efficacy of cisplatin–vinorelbine therapy in malignant pleural mesothelioma

    • Zarah Glad Zimling
    • Jens Benn Sørensen
    • Eric Santoni-Rugiu

    Original Article 08 September 2012 Pages: 743 - 754

    

15. Phase I trial of pomalidomide given for patients with advanced solid tumors

    • Matthew M. Cooney
    • Charles Nock
    • Afshin Dowlati

    Clinical Trial Report 09 August 2012 Pages: 755 - 761

16. Erratum to: The “survivin suppressants” NSC 80467 and YM155 induce a DNA damage response

    • Trevor G. Glaros
    • Luke H. Stockwin
    • Dianne L. Newton

    Erratum 30 September 2012 Pages: 763 - 764